98%
921
2 minutes
20
In spite of various research investigations towards anti-depressant drug discovery program, no one drug has not yet launched last 20 years. Corticotropin-releasing factor-1 (CRF-1) is one of the most validated targets for the development of antagonists against depression, anxiety and post-traumatic stress disorders. Various research studies suggest that pyrazinone based CRF-1 receptor antagonists were found to be highly potent and efficacious. In this research investigation, we identified the pharmacophore and binding pattern through 2D and 3D-QSAR and molecular docking respectively. Molecular dynamics studies were also performed to explore the binding pattern recognition. We establish the relationship between activity and pharmacophoric features to design new potent compounds. The best 2D-QSAR model was generated through multiple linear regression method with value of 0.97 and value of 0.89. Also 3D-QSAR model was obtained through k-nearest neighbor molecular field analysis method with value of 0.52 and _se value of 0.36. Molecular docking and binding energy were also evaluated to define binding patterns and pharmacophoric groups, including (i) hydrogen bond with residue Asp284, Glu305 and (ii) π-π stacking with residue Trp9. Compound has the highest binding affinity compared to reference compounds, so this compound could be a potent drug for stress related disorders. Most of the compounds, including reference compounds were found within acceptable range of physicochemical parameters. These observations could be provided the leads for the design and optimization of novel CRF-1 receptor antagonists. Communicated by Ramaswamy H. Sarma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/07391102.2018.1513379 | DOI Listing |
Trials
August 2025
Copenhagen Research Center for Biological and Precision Psychiatry, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Background: Globally, depression represents one of the leading causes of years lived with disability. The effects of current pharmacological treatments are small-to-moderate and often delayed by weeks. Immunological disturbances have been associated with depression and meta-analyses have suggested that anti-inflammatory agents have moderate-to-large anti-depressant effects.
View Article and Find Full Text PDFSci Rep
August 2025
Herbal Pharmacology Research Center, TeMS.C., Islamic Azad University, Tehran, Iran.
Schizophrenia is a severe chronic neuropsychiatric disorder with a wide-range of cognitive and mental deficits and different categories of symptoms including positive, negative, and cognitive symptoms. In rodents, sub-chronic ketamine administration is a common method to induce a schizophrenia-like state. Olanzapine, an atypical antipsychotic medication, is used for the treatment and management of schizophrenia symptoms.
View Article and Find Full Text PDFReproduction
September 2025
CReATe Fertility Centre, Toronto, Ontario, Canada.
In Brief: Generalized anxiety disorder, major depressive disorder and their treatment selective serotonin reuptake inhibitors (SSRIs) impact 4-17% of pregnancies worldwide and alter the epigenome of numerous tissues, but their effects on the ovarian follicle are unknown. This study profiles the methylome of granulosa cells, revealing novel epigenetic pathways and molecular mechanisms altered by mental health conditions and their treatments.
Abstract: Generalized anxiety and major depressive disorders (GAD/MDD) impact 4-17% of pregnancies worldwide.
J Microbiol Biotechnol
August 2025
Central R&D Center, B&Tech Co., Ltd., Naju 58205, Republic of Korea.
L. is a traditional medicinal plant known for its therapeutic potential in mental disorders, including depression. Previous studies have reported its antidepressant-like effects in animal models, primarily attributed to curcumin, its major bioactive compound.
View Article and Find Full Text PDFBehav Brain Res
October 2025
Department of Brain Sciences, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Republic of Korea. Electronic address:
Depression is a common cause of mental illness in the modern world, and the wide variation in symptoms makes it difficult to develop suitable antidepressants. The commonly used serotonin reuptake inhibitors (SSRIs) cause many side effects, making it imperative to develop alternative treatments. GV1001, a 16-amino acid peptide derived from human telomerase reverse transcriptase, has shown various neuroprotective effects in recent studies.
View Article and Find Full Text PDF